• 1
    Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005; 117: 294-299.
  • 2
    Travis WD, Brambilla E, Muller-Hemelink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumous of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
  • 3
    Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the. 2004 World Health Organization pathologic criteria. J Thorac Oncol. 2006; 1( 9 suppl): S13-S19.
  • 4
    Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002; 26: 358-364.
  • 5
    Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology. 2005; 46: 677-684.
  • 6
    Miyoshi T, Satoh Y, Okumura S, et al. Early stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol. 2003; 27: 101-109.
  • 7
    Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol. 2008; 39: 324-330.
  • 8
    Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32: 810-827.
  • 9
    Anami Y, Iijima T, Suzuki K, et al. Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis. J Thorac Oncol. 2009; 4: 951-958.
  • 10
    Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010; 116: 659-669.
  • 11
    Bryant CM, Albertus DL, Kim S, et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study [serial online]. PLoS One. 2010; 5: e11712.
  • 12
    Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y. Surgically curable “early” adenocarcinoma in the periphery of the lung. Am J Surg Pathol. 1994; 18: 431-438.
  • 13
    Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol. 2010; 5: 333-339.
  • 14
    Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995; 75: 2844-2852.
  • 15
    Okudela K, Woo T, Mitsui H, et al. Proposal of an improved histological subtyping system for lung adenocarcinoma—significant prognostic values for stage I disease. Int J Clin Exp Pathol. 2010; 3: 348-366.
  • 16
    Petersen I, Kotb WF, Friedrich KH, Schluns K, Bocking A, Dietel M. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer. 2009; 65: 312-318.
  • 17
    Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg. 2006; 81: 1988-1995.
  • 18
    Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011; 6: 1496-1504.
  • 19
    Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg. 2004; 78: 1728-1733.
  • 20
    Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004; 28: 198-206.
  • 21
    Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010; 34: 1155-1162.
  • 22
    Sorensen JB, Hirsch FR, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease. Cancer. 1988; 62: 361-367.
  • 23
    Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003; 27: 937-951.
  • 24
    Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24: 653-664.
  • 25
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008; 359: 1367-1380.
  • 26
    Sudhindra A, Ochoa R, Santos ES. Biomarkers, prediction, and prognosis in nonsmall-cell lung cancer: a platform for personalized treatment [published online ahead of print May 8, 2011]. Clin Lung Cancer. 2011.
  • 27
    Tang X, Kadara H, Behrens C, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011; 17: 2434-2443.
  • 28
    Kadara H, Behrens C, Yuan P, et al. A 5-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2010; 17: 1490-1501.
  • 29
    Kadara H, Lacroix L, Behrens C, et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009; 2: 702-711.
  • 30
    Bingle CD. Thyroid transcription factor-1. Int J Biochem Cell Biol. 1997; 29: 1471-1473.
  • 31
    Moldvay J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res. 2004; 10: 85-88.
  • 32
    Barlesi F, Pinot D, Legoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer. 2005; 93: 450-452.
  • 33
    Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009; 13( 8B): 1977-1986.
  • 34
    Berghmans T, Mascaux C, Haller A, Meert AP, Van Houtte P, Sculier JP. EGFR, TTF-1 and Mdm2 expression in stage III nonsmall cell lung cancer: a positive association. Lung Cancer. 2008; 62: 35-44.
  • 35
    Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP. Prognostic role of thyroid transcription factor-1 in stage III nonsmall cell lung cancer. Lung Cancer. 2006; 52: 219-224.
  • 36
    Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene. 2008; 27: 3635-3640.
  • 37
    Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000; 18: 106-115.
  • 38
    Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136: 260-271.
  • 39
    Silver SA, Askin FB. True papillary carcinoma of the lung: a distinct clinicopathologic entity. Am J Surg Pathol. 1997; 21: 43-51.
  • 40
    Moran CA. Pulmonary adenocarcinoma: the expanding spectrum of histologic variants. Arch Pathol Lab Med. 2006; 130: 958-962.
  • 41
    Borczuk AC. Micropapillary histology: a frequent morphology of mutation-associated lung adenocarcinoma? Am J Clin Pathol. 2009; 131: 615-617.
  • 42
    Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in nonsmall cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010; 16: 3743-3753.
  • 43
    Kalbfleischl JD, Prentice RL. The Statistical Analysis of Failure Time Data (Wiley Series in Probability and Statistics). 2nd ed. New York: John Wiley & Sons, Inc.; 2002.
  • 44
    Haruki T, Shomori K, Shiomi T, Taniguchi Y, Nakamura H, Ito H. The morphological diversity of small lung adenocarcinoma with mixed subtypes is associated with local invasiveness and prognosis. Eur J Cardiothorac Surg. 2011; 39: 763-768.
  • 45
    Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
  • 46
    Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009; 27: 271-278.